Frazier Life Sciences Management, L.P. Phathom Pharmaceuticals, Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $1.9 Billion
- Q2 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 12,466,489 shares of PHAT stock, worth $151 Million. This represents 6.31% of its overall portfolio holdings.
Number of Shares
12,466,489
Previous 10,109,279
23.32%
Holding current value
$151 Million
Previous $63.4 Million
88.61%
% of portfolio
6.31%
Previous 3.99%
Shares
4 transactions
Others Institutions Holding PHAT
# of Institutions
138Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Medicxi Ventures Management (Jersey) LTD7.46MShares$90.3 Million20.28% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$50.1 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$42.3 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$35.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.79MShares$33.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $474M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...